HC Wainwright Reaffirms “Buy” Rating for Actinium Pharmaceuticals (NYSE:ATNM)

HC Wainwright restated their buy rating on shares of Actinium Pharmaceuticals (NYSE:ATNM) in a research report report published on Friday morning, Benzinga reports. The brokerage currently has a $50.00 price target on the stock.

Several other analysts also recently issued reports on the company. StockNews.com upgraded Actinium Pharmaceuticals from a sell rating to a hold rating in a research note on Sunday, May 5th. Cantor Fitzgerald reiterated an overweight rating and set a $21.00 price target on shares of Actinium Pharmaceuticals in a research note on Tuesday, April 30th. Finally, Stephens initiated coverage on Actinium Pharmaceuticals in a research note on Tuesday, May 14th. They set an overweight rating and a $25.00 price target for the company. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and an average price target of $25.60.

Actinium Pharmaceuticals Trading Down 6.9 %

Shares of ATNM stock opened at $7.28 on Friday. Actinium Pharmaceuticals has a fifty-two week low of $4.00 and a fifty-two week high of $10.24. The stock has a market capitalization of $216.80 million, a price-to-earnings ratio of -4.26 and a beta of 0.20.

Actinium Pharmaceuticals (NYSE:ATNM) last issued its earnings results on Friday, April 26th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.11. Equities research analysts expect that Actinium Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Institutional Trading of Actinium Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in Actinium Pharmaceuticals by 6.0% during the 1st quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock valued at $11,325,000 after purchasing an additional 82,113 shares during the period. Bank of New York Mellon Corp raised its holdings in Actinium Pharmaceuticals by 28.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 86,401 shares of the company’s stock valued at $639,000 after acquiring an additional 19,035 shares in the last quarter. Virtu Financial LLC raised its holdings in Actinium Pharmaceuticals by 319.2% in the 1st quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock valued at $642,000 after acquiring an additional 62,459 shares in the last quarter. Finally, Sanders Morris Harris LLC acquired a new position in Actinium Pharmaceuticals in the 1st quarter valued at approximately $78,000. Institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.